63
Views
12
CrossRef citations to date
0
Altmetric
Review

Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson’s disease

, , &
Pages 91-97 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Alexander S. Wang & Steven A. Gunzler. (2019) Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opinion on Pharmacotherapy 20:13, pages 1659-1670.
Read now
Jens P Reese, Judith Dams, Yaroslav Winter, Monika Balzer-Geldsetzer, Wolfgang H Oertel & Richard Dodel. (2012) Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Expert Opinion on Pharmacotherapy 13:7, pages 939-958.
Read now
Leslie J Findley, Andrew Lees, Marjo Apajasalo, Anna Pitkänen & Heidi Turunen. (2005) Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Current Medical Research and Opinion 21:7, pages 1005-1014.
Read now

Articles from other publishers (9)

Anna Nikl, Mathieu F. Janssen, Valentin Brodszky & Fanni Rencz. (2023) A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample. Health and Quality of Life Outcomes 21:1.
Crossref
J. D. Suquilanda-Pesántez, M. C. Zambonino-Soria, D. E. López-Ramos, M. G. Pineda-Molina, N. S. Milán, M. C. Muñoz, G. F. Villalba-Meneses & D. Almeida-Galárraga. 2021. Artificial Intelligence, Computer and Software Engineering Advances. Artificial Intelligence, Computer and Software Engineering Advances 3 18 .
Judith Dams, Bernhard Bornschein, Jens Peter Reese, Annette Conrads-Frank, Wolfgang H. Oertel, Uwe Siebert & Richard Dodel. (2011) Modelling the Cost Effectiveness of Treatments for Parkinsonʼs Disease. PharmacoEconomics 29:12, pages 1025-1049.
Crossref
James Shearer, Colin Green, Carl E. Counsell & John P. Zajicek. (2011) The Use of Decision-Analytic Models in Parkinsonʼs Disease. Applied Health Economics and Health Policy 9:4, pages 243-258.
Crossref
Ariel Gordin & David J. Brooks. (2007) Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. Journal of Neurology 254:S4, pages IV37-IV48.
Crossref
Joumana Hudry, Juha O Rinne, Tapani Keränen, Laurent Eckert & John M Cochran. (2016) Cost-Utility Model of Rasagiline in the Treatment of Advanced Parkinson's Disease in Finland. Annals of Pharmacotherapy 40:4, pages 651-657.
Crossref
Anja Tuulonen & Harri Sintonen. 2006. Glaucoma. Glaucoma 123 133 .
Uwe Siebert, Bernhard Bornschein, Tobias Walbert & Richard C. Dodel. (2004) Systematic Assessment of Decision Models in Parkinson's Disease. Value in Health 7:5, pages 610-626.
Crossref
Tim Ibbotson & Karen L. Goa. (2002) Management of Parkinson??s Disease. Disease Management & Health Outcomes 10:10, pages 643-659.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.